Nrx pharmaceuticals to lead development of covid-19 medicines and vaccines in central europe and the caucasus region in collaboration with the lugar institute and cromos pharma

Radnor, pa., may 26, 2021 /prnewswire/ -- today, nrx pharmaceuticals, inc., (nasdaq:nrxp) (nrx) through its georgia subsidiary,  announced that it has signed a master services agreement with cromos pharma, llc, headquartered in longview, washington,  to conduct phase 3 clinical trials of covid-19 related drugs and vaccines in central europe and the caucasus region.
NRXP Ratings Summary
NRXP Quant Ranking